DCGI

COVID-19: Pharma giants seek DCGI's approval to manufacture, sell Remdesivir drug

However, multiple additional clinical trials are ongoing to generate more data on the safety and efficacy of Remdesivir as a treatment for COVID-19.

published on : 4th June 2020

Biocon gets DCGI nod for device to treat critical COVID-19 patients

Biocon Biologics, a unit of the company, has got DCGI nod for an extracorporeal blood purification device CytoSorb to reduce pro-inflammatory cytokines levels.

published on : 27th May 2020